


Product Name : DT2216
Cat. No. : PC-38054
CAS No. : 2365172-42-3
Molecular Formula : C₇₇H₉₆ClF₃N₁₀O₁₀S₄
Molecular Weight : 1542.36
Target : PROTAC
Solubility : 10 mM in DMSO



Biological Activity

DT2216 (DT-2216) is a specific **BCL-XL PROTAC** by linking ABT263 to a VHL ligand (VHL-L), induces BCL-XL degradation in MOLT-4 T-ALL cells with DC50 of 63 nM.

DT2216 exhibits improved antitumor potency (MOLT-4 cells EC50=52 nM) but reduced platelet toxicity by targeting BCL-XL to the VHL E3 ligase for degradation.

DT2216 degrades BCL-XL in a VHL- and proteasome-dependent manner.

DT2216 demonstrates increased antitumor activity of DT2216 in combination with other BCL-2 family protein inhibitors (ABT199 and S63845) and chemotherapy.

DT2216 sensitizes drug resistant tumor cells to chemotherapy in vivo.

References

Khan S, et al. *Nat Med*. 2019 Dec;25(12):1938-1947.

Cancer Discov. 2020 Feb;10(2):174.

Thummuri D, et al. *Mol Cancer Ther*. 2022 Jan;21(1):184-192.

He Y, et al. *J Hematol Oncol*. 2020 Jul 16;13(1):95.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com